Snoring — Symptoms, Causes & Treatment | MyMedicPlus

Snoring is the sound produced by turbulent airflow causing vibration of the relaxed pharyngeal soft tissues — primarily the soft palate and uvula, with contributions from the tonsillar pillars, lateral pharyngeal walls, and tongue base — during inspiration (and sometimes expiration) in sleep. During wakefulness, pharyngeal muscle tone maintains an open airway; during sleep, progressive muscle relaxation narrows the upper airway, and if the airway narrows sufficiently that airflow becomes turbulent and tissues begin to flutter, snoring results. Approximately 45% of adults snore occasionally and approximately 25% habitually (every night or most nights) — making it one of the most prevalent sleep-related complaints. Snoring is more common in men (male-to-female ratio approximately 2:1 in middle age, converging in older age) and increases in prevalence with age, obesity, alcohol use, and sedative medication use. The clinical importance of snoring lies in the distinction between primary (simple or benign) snoring — airway vibration without significant respiratory obstruction or sleep disruption — and snoring as a manifestation of obstructive sleep apnoea (OSA). OSA is defined by the American Academy of Sleep Medicine (AASM) as an apnoea-hypopnoea index (AHI) of 5 or above events per hour of sleep — repeated episodes of partial (hypopnoea — reduced airflow with oxygen desaturation or arousal) or complete (apnoea — no airflow for 10 seconds or more) upper airway obstruction during sleep, causing intermittent nocturnal hypoxia, sleep fragmentation, and daytime symptoms. OSA affects approximately 15-30% of males and 5-15% of females — the majority undiagnosed. Untreated OSA carries significant cardiovascular, metabolic, and neurological consequences distinct from simple snoring, making clinical evaluation of all habitual snorers essential to identify those who have OSA requiring treatment.

Obesity and excess body weight: the most important modifiable risk factor for snoring and OSA; fat deposition in the parapharyngeal tissues, soft palate, and lateral pharyngeal walls directly reduces the pharyngeal lumen cross-sectional area; a 10% increase in body weight increases OSA risk by approximately 32%; conversely, 10% weight loss reduces the AHI by 26% and often substantially reduces snoring severity. Nasal obstruction: the nasal airway provides approximately 50% of total airway resistance during quiet breathing; any condition increasing nasal resistance forces oral breathing (mouth breathing collapses the oropharyngeal airway further); causes include allergic rhinitis (the most common — affects 20-30% of the population and significantly worsens snoring seasonally or perennially), deviated nasal septum (traumatic or congenital — unilateral obstruction redirecting airflow), nasal polyps (from chronic rhinosinusitis — bilateral obstruction), and turbinate hypertrophy (inferior turbinate enlargement from chronic allergic or non-allergic rhinitis). Alcohol and sedating medications: the most common modifiable acute precipitant of snoring — even small amounts of alcohol (1-2 units within 3-4 hours of sleep) significantly increase snoring frequency and loudness by reducing pharyngeal muscle tone and suppressing arousal responses; sedating medications with the same mechanism include benzodiazepines, non-benzodiazepine hypnotics (zolpidem, zopiclone), opioids, antihistamines, and muscle relaxants. Anatomical predisposition: retrognathia or micrognathia (receded lower jaw — reduces the mandibular space for the tongue, causing posterior tongue displacement); macroglossia (large tongue from obesity or congenital causes); enlarged tonsils and adenoids (particularly in children — the most common cause of childhood snoring and paediatric OSA); elongated or bulky soft palate and uvula; and low-lying hyoid bone. Smoking: mucosal oedema and inflammation of the upper airway from tobacco smoke chemical irritation increases airway resistance and tissue vibratability; smokers have approximately 2x the snoring risk of non-smokers. Hypothyroidism: causes tongue enlargement (macroglossia), pharyngeal mucosal oedema, and reduced pharyngeal muscle tone — all increasing snoring risk; thyroid function tests should be checked in all patients with unexplained weight gain and snoring. Supine sleeping position: gravity pulls the tongue, soft palate, and uvula posteriorly in the supine position, further narrowing the retrolingual and retropalatal airway — many patients snore exclusively or predominantly when sleeping on their back (positional snoring or positional OSA).

The primary presenting feature: loud, rhythmic or irregular respiratory sounds during sleep — typically described by a bed partner, and often the reason for the clinical consultation, as the snorer themselves is usually unaware of the noise. Snoring arising from the soft palate tends to be rhythmic; tongue-base snoring tends to be more irregular; positional snorers only produce noise in the supine position. The clinical distinction between simple snoring and obstructive sleep apnoea (OSA) relies on identifying the additional features that accompany snoring in OSA: Witnessed apnoeas — the bed partner observes the patient stop breathing for 10 seconds or more and then gasp, choke, or snort loudly as the obstruction is broken by an arousal; this symptom, when reliably reported by a partner, is highly specific for OSA (sensitivity ~70%, specificity ~95%) and should always prompt formal sleep investigation. Excessive daytime sleepiness (EDS) — the cardinal symptom of OSA — caused by repeated nocturnal arousal from apnoeic events fragmenting sleep and preventing restorative slow-wave sleep; EDS is quantified using the Epworth Sleepiness Scale (ESS — a score of 10 or above, or specifically falling asleep while driving, eating, or in conversation, indicates clinically significant sleepiness requiring urgent assessment); simple primary snoring does NOT cause EDS; EDS in a snorer strongly suggests OSA. Non-restorative or unrefreshing sleep — waking feeling unrefreshed and exhausted despite an apparently adequate sleep duration. Morning headaches (occipital or generalised) — from nocturnal hypercapnia (CO2 accumulation) during apnoeic episodes causing cerebral vasodilation; present in 20-30% of OSA patients. Nocturia — waking to void 2 or more times per night is common in moderate-severe OSA from atrial natriuretic peptide release triggered by intrathoracic pressure fluctuations during apnoeas. Cognitive impairment: concentration difficulty, memory impairment, and slowed processing speed from sleep fragmentation and intermittent nocturnal hypoxia. Mood disturbance: irritability, depression, and anxiety — often attributed to other causes and unrecognised as OSA sequelae. Dry mouth, sore throat, and mouth breathing on waking from nasal obstruction forcing oral breathing. In children: snoring with mouth breathing, restless sleep, nocturnal enuresis (bedwetting), behaviour problems, and impaired school performance are the characteristic presentation of paediatric OSA from adenotonsillar hypertrophy.

Clinical history and partner report: detailed history from both the patient and their sleeping partner (if available) covering snoring frequency and loudness, witnessed apnoeas (the most important discriminating symptom), nocturnal choking or gasping, daytime sleepiness (Epworth Sleepiness Scale), nocturia, morning headaches, and cognitive or mood changes. Validated screening questionnaires: STOP-BANG questionnaire (8 yes/no questions: Snoring loud enough to be heard through closed doors; Tired or fatigued most days; Observed breathing stopping during sleep; blood Pressure treated or above 140/90; BMI above 35; Age above 50; Neck circumference above 40 cm; Gender male) — a score of 3 or above indicates intermediate-to-high OSA risk and warrants objective sleep testing; sensitivity for moderate-severe OSA is 90-95% at a score above 2. Epworth Sleepiness Scale (ESS): 8 self-rated scenarios of daytime somnolence; a score of 10 or above indicates significant EDS warranting sleep investigation; a score of 16 or above indicates severe sleepiness with significant safety implications (DVLA duty to report EDS that may impair driving). Objective sleep investigation: home sleep apnoea testing (HSAT) — a limited channel portable monitor recording airflow (nasal pressure cannula and thermistor), respiratory effort (thoracoabdominal bands), oxygen saturation (SpO2 via pulse oximetry), heart rate, and body position; widely recommended as the first-line investigation for suspected moderate-severe OSA in uncomplicated patients — provides the AHI from the recording; cheaper and more accessible than in-laboratory polysomnography (PSG). Polysomnography (PSG) — the gold standard comprehensive sleep study: performed in a sleep laboratory with overnight monitoring of EEG (sleep staging), EOG (eye movements), EMG (muscle tone), airflow, respiratory effort, SpO2, ECG, body position, and audio-video recording; provides AHI, sleep architecture, oxygen desaturation index, and identifies other sleep disorders; required for complex cases (suspected central sleep apnoea, atypical presentations, CPAP titration failure, or perioperative assessment). Nasopharyngoscopy (flexible nasal endoscopy): performed in clinic to directly visualise the nasal airway, nasopharynx, oropharynx, soft palate, and hypopharynx; identifies the anatomical sites of obstruction; the Muller manoeuvre (asking the patient to make an inspiratory effort against a closed mouth and nose) dynamically assesses pharyngeal collapse pattern under simulated sleep conditions. Thyroid function tests: TSH and free T4 in all patients with unexplained weight gain, fatigue, and snoring.

Weight loss (most effective long-term treatment — 10% weight loss significantly reduces snoring severity). Positional therapy: anti-snore pillows, positional devices to maintain side-sleeping. Nasal strips/dilators (limited evidence). Mandibular advancement device (MAD/oral appliance): effective for simple snoring and mild-moderate OSA. CPAP if OSA confirmed (most effective). Surgery: septoplasty (deviated septum), tonsillectomy, palate surgery (UPPP/LAUP — variable long-term results), or radiofrequency tongue base reduction. Regular monitoring of treatment response, early detection of side effects, and ongoing assessment of disease progression are essential components of optimising patient outcomes over the long term. Treatment plans should be proactively reviewed and appropriately adjusted based on clinical response, patient-reported tolerability, changing patient circumstances, and continuously evolving evidence-based clinical guidelines. Meaningful shared decision-making between patients and their healthcare team, incorporating patient values and treatment preferences, consistently improves both treatment adherence and long-term outcomes.

Primary snoring: significant impact on bed partner sleep quality and relationship. If OSA is present and untreated: hypertension, cardiovascular disease (atrial fibrillation, MI, stroke), type 2 diabetes, motor vehicle accidents (3-7x increased risk), cognitive impairment, and depression. Untreated snoring in children (adenotonsillar hypertrophy) causes behavioral problems, growth delay, and poor academic performance. Long-term specialist follow-up and structured regular review are essential to detect and appropriately manage complications at the earliest possible stage, minimising long-term disability, preserving organ function, and improving the overall prognosis. Patient education about the early warning signs of complications and clear guidance on when to seek urgent medical attention empowers timely help-seeking behaviour and reduces preventable serious adverse outcomes. Psychological impact — including depression, anxiety, and reduced quality of life — should be proactively assessed and addressed as part of comprehensive complication management.

Weight loss is the most effective long-term treatment for obesity-related snoring and OSA: a 10% reduction in body weight reduces the AHI by approximately 26%, and significant weight loss (20-30%) can produce complete resolution in a substantial proportion of obese patients; caloric deficit of 500-750 kcal per day combined with regular exercise is the recommended approach; weight-loss medications (GLP-1 receptor agonists such as semaglutide — tirzepatide) have shown remarkable efficacy in reducing body weight and have associated improvements in OSA severity in trials. Positional therapy: sleeping in the lateral (side-lying) position rather than supine reduces snoring in 50-60% of positional snorers; practical strategies include the 'tennis ball' technique (sewing a tennis ball into the back of pyjamas to prevent supine rolling), positional devices (back-alarm vibrators that alert to supine rolling), specially shaped positional pillows, and the WEDGEpillow; an elevated head of bed (30-degree elevation) also reduces airway collapse from gravity. Alcohol and sedative reduction: eliminating or substantially reducing alcohol within 3-4 hours of bedtime is among the most impactful lifestyle changes — even one glass of wine before bed increases snoring frequency and loudness; benzodiazepines, antihistamines, and opioid analgesics should be avoided where possible in the evening. Nasal congestion management: intranasal corticosteroid spray (INCS — mometasone, fluticasone propionate) for allergic or non-allergic rhinitis significantly improves nasal patency, reducing mouth breathing and snoring; nasal saline irrigation (isotonic or hypertonic) reduces mucosal oedema; nasal dilator strips (Breathe Right type) have modest evidence for primary snoring from nasal valve collapse. Smoking cessation: reduces pharyngeal mucosal inflammation and airway oedema within weeks of stopping. Excusion of OSA: all habitual snorers with any of the following should receive formal sleep investigation before relying solely on lifestyle measures — excessive daytime sleepiness (ESS above 10), witnessed apnoeas, morning headaches, nocturnal choking or gasping, STOP-BANG score above 2, or cardiovascular risk factors. Treating confirmed OSA with CPAP addresses both the OSA and its snoring component — CPAP eliminates snoring in 90%+ of cases.

See your GP promptly for assessment if you or your partner are experiencing snoring alongside any of the following — which suggest obstructive sleep apnoea (OSA) rather than simple snoring: witnessed pauses in breathing during sleep — your partner observes you stop breathing for 10 seconds or more and then gasp or snort; waking up choking or gasping for breath; excessive daytime sleepiness despite sleeping 7-8 hours — falling asleep at inappropriate times (during conversation, driving, in meetings) is a sign of OSA and significantly increases road accident risk (DVLA regulations may apply); morning headaches most days — may indicate nocturnal hypoxia; STOP-BANG score of 3 or more: Snoring, Tired, Observed apnoeas, blood Pressure high, BMI over 35, Age over 50, Neck over 40 cm, male Gender. Seek same-day or emergency care if: you experience heart palpitations, chest pain, or breathlessness alongside snoring — OSA is strongly associated with atrial fibrillation and nocturnal cardiac events; a child has significant witnessed breathing pauses with snoring and daytime behaviour problems or growth delay — paediatric ENT review needed. Snoring without any of the above can be managed initially with lifestyle measures (weight loss, positional therapy, alcohol reduction) and pharmacist advice before GP assessment.